In vitro boost of human NK activity by a triethylphosphine gold derivative.
Human PBL incubated in vitro with the new anti-rheumatic drug triethylphosphine gold (Auranofin) show a rapid concentration-dependent increase in NK reactivity to a variety of targets (Raji, K-562, HAE 70). The process is not affected by major changes in the proportion of monocytes present and is only slightly affected by actinomycin D or cycloheximide. In contrast to TPG, the effect of interferon is to boost the activity of K cells as well as NK cells, and this boost appears to be more sensitive to inhibition of protein or RNA synthesis. These factors suggest that TPG may be working through a different mechanism.
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D003601:Cytotoxicity Tests, Immunologic; D003609:Dactinomycin / Q000494:pharmacology; D006046:Gold / Q000031:analogs & derivatives*; D006801:Humans; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D008214:Lymphocytes / Q000276:immunology; D014176:Protein Biosynthesis; D012313:RNA / Q000096:biosynthesis
D000893:Anti-Inflammatory Agents; D003609:Dactinomycin; D006051:Aurothioglucose; D001310:Auranofin; D012313:RNA; D006046:Gold; D003513:Cycloheximide